Composition of Matter Patent and Translational Research Grant issued for ONC213Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,266,533 entitled “7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO [3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY†with an expiration date of January 29, 2036. This patent covers the composition of matter for ONC213, its di-salt formulation, and its use in the treatment of cancer. In addition to the claims related to ONC213, the patent also contains claims for millions of structurally-related imipridones. ONC213 is the fourth molecule in the…
Author: Editor
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda In Depth, Enhancing Chemo & Radiotherapies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda & Isoflavonoid Studies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Developing Isoflavone Idronoxil For Oncology Purposes.
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Noopur Raje provides an update on the standard of care for maintenance therapy in patients with multiple myeloma. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Jonathan L. Kaufman provides an update on first line therapy for multiple myeloma. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Thomas G. Martin discusses emerging immunotherapies for the treatment of multiple myeloma. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Saad Z. Usmani discusses recent advances in small molecule inhibition for the treatment of multiple myeloma. © 2019 Imedex, an HMP Company
Philadelphia, PA (April 24, 2019) – Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant to a research team at University of California, Los Angeles to perform a natural disease history study of adult midline gliomas, a certain type of aggressive brain tumors. The study will follow patients from first diagnosis through a series of therapeutic interventions that for a subset of patients will include ONC201, an investigational agent in clinical trials for H3 K27M-mutant gliomas that has induced radiographic regressions in some patients.“Novel therapies are desperately needed for treatment of H3 K27M-mutant gliomas,†said…
test video spanish upload
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Engineering EBV Specific T cells.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Mesothelin Targeted CAR-T Study.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses EBV CD19 CAR-T Cells Potency.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Subset Of 11 Mesothelioma Patients.
NEW DATA SHOW BLUEPRINT® IDENTIFIES ESTROGEN RECEPTOR POSITIVE BREAST CANCER PATIENTS WITH POOR RESPONSE TO ANTI-ESTROGEN THERAPY WHO MAY BENEFIT FROM NEOADJUVANT CHEMOTHERAPY  ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools  Results published in Nature Publishing Group’s npj Breast Cancer  IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS –24 April, 2019 – Agendia, Inc., a world leader in precision oncology, today announced the publication of study results for BluePrint®, its 80-gene proprietary molecular subtyping test, in Nature Breast Cancer. It is well known that a significant subset of patients diagnosed with early stage, estrogen…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Understanding Early Onset Colorectal Cancer.
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Molecular Signatures In Colorectal Cancer.
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Increasing Incidences In Colorectal Cancer.
Vishwas Paralkar PhD, Cybrexa Chief Scientific Officer Discusses Combining Alphalex Technology With Rucaparib.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses What IRAK4 Degredation Offers.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses The Future Of The IRAK4 Degrader.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Protein Degradation Technology.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Elaborating On The IRAK4 Protein Degrader
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses E3 Ligase Atlas In Development.
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses Novel Oral HIF-2 Alpha Inhibitor PT2977. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses mTOR & PI3 Kinase Inhibitor Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses Elaborating On Frontline Therapies. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine At The Keck School Of Medicine Talks About Remembering Martin Gore. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine At The Keck School Of Medicine Discusses Debate On Cytoreductive Nephrectomy. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Jose Karam M.D., FACS Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston, Texas Discusses Neoadjuvant Trials In Kidney Cancer. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave Roussy Discusses Treating Brain Metastases From RCC With Nivolumab. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave Roussy Discusses Is HIF Inhibition The Right Target In RCC. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgical Consequences Of Pretreating Patients With RCC. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgery Or Therapy First. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Elaborating On The CARMENA Trial. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Perioperative Therapy In The CARMENA & PROBE Trials. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.
We are pleased to share with you the videos from the live webcast. In this 5th video, the panel opens up for a Q&A session. For more we invite you to visit https://cancerGRACE.org
We are pleased to share with you the videos from the live webcast. In this 4th video, Dr. H. Jack West discusses “Systemic Therapies for Advanced NSCLC”. For more we invite you to visit https://cancerGRACE.org
We are pleased to share with you the videos from the live webcast. In this 3rd video, Dr. Eric Vallieres discusses “The Growing Potential Utility of Surgery in Advanced NSCLC”. For more we invite you to visit https://cancerGRACE.org
We are pleased to share with you the videos from the live webcast. In this 2nd video, Dr. Puneeth Iyengar discusses “Novel Indications for Local Therapy in Advanced NSCLC”.
We are pleased to share with you the videos from the live webcast. In this first video, Dr. West introduces the program and shares the floor with Dr. Vivek Mehta who discusses “Newer Technologies in Radiation”.
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Why One Year Of Treatment With Dosing Of Drugs. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Elaborating On Multiple Kidney Cancer Studies. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Two IO Plus TKI Studies In Kidney Cancer. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Treating Renal Masses with Minimal Invasive Ablative Technique. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Criteria To Indicate Delayed Intervention After Inductive Surveillance. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses When Can cfDNA Profiling Be Applicable. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Understanding Biology With ADAPTeR Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019